Search
3-Phosphoglycerate Dehydrogenase Deficiency
smpdb.ca/view/SMP0000721Disease3-Phosphoglycerate dehydrogenase deficiency is a disorder of L-serine biosynthesis that is characterized by congenital microcephaly, psychomotor retardation, and seizures.The disorder is caused by homozygous or compound heterozygous or h...
Drugs: Pyridoxal phosphate · Tetrahydrofolic acid · Ademetionine · Pyruvic acid · Arginine · Adenosine phosphate +26 moreEnzymes: Betaine--homocysteine S-methyltransferase 1Nilotinib Inhibition of BCR-ABL Action Pathway
smpdb.ca/view/SMP0031697Drug actionNilotinib is a tyrosine kinase inhibitor used to treat chronic myelogenous leukemia (CML), a cancer characterized by increased and unregulated growth of white blood cells in the bone marrow and the accumulation of these cells in the bloo...
Drugs: NilotinibEnzymes: S-phase kinase-associated protein 2Asciminib Inhibition of BCR-ABL
smpdb.ca/view/SMP0126943Drug actionAsciminib is an inhibitor of ABL/BCR-ABL1 tyrosine kinase for the treatment of patients with Philadelphia chromosome-positive CML, including those with the T315I mutation. Asciminib is an allosteric inhibitor of the BCR-ABL1 tyrosine kin...
Drugs: AsciminibEnzymes: S-phase kinase-associated protein 2Belimumab
go.drugbank.com/drugs/DB08879ApprovedInvestigationalBelimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. … It is produced by recombinant DNA technology in a murine cell (NS0) expression system.
Categories: Decreased B Lymphocyte Activation, B Lymphocyte Stimulator-specific InhibitorProducts: BENLYSTIA SC, BENLYSTA 200 MG / 1 MLDimethylglycine Dehydrogenase Deficiency
smpdb.ca/view/SMP0000484DiseaseDimethylglycine dehydrogenase deficiency, also called DMGDH deficiency and dimethylglycinuria, is a rare inborn error of metabolism (IEM) and autosomal recessive disorder of glycine metabolism caused by a defective DMGDH gene. DMGDH code...
Drugs: Pyridoxal phosphate · Tetrahydrofolic acid · Ademetionine · Pyruvic acid · Arginine · Adenosine phosphate +26 moreEnzymes: Betaine--homocysteine S-methyltransferase 1Dasatinib Inhibition of BCR-ABL Action Pathway
smpdb.ca/view/SMP0031696Drug actionDasatinib is a tyrosine kinase inhibitor used to treat chronic myelogenous leukemia (CML), a cancer characterized by increased and unregulated growth of white blood cells in the bone marrow and the accumulation of these cells in the bloo...
Drugs: DasatinibEnzymes: S-phase kinase-associated protein 2Bafetinib Inhibition of BCR-ABL Action Pathway
smpdb.ca/view/SMP0031699Drug actionBafetinib is a tyrosine kinase inhibitor used to treat chronic myelogenous leukemia (CML), a cancer characterized by increased and unregulated growth of white blood cells in the bone marrow and the accumulation of these cells in the bloo...
Drugs: BafetinibEnzymes: S-phase kinase-associated protein 2Non-Ketotic Hyperglycinemia
smpdb.ca/view/SMP0125580DiseaseNon Ketotic Hyperglycinemeia (Glycine encephalopathy; Glycine cleavage system deficiency; NKH) is caused by mutations in several genes in the mitochondrial glycine cleavage system. These include the genes encoding P protein (GLDC), T pro...
Drugs: Pyridoxal phosphate · Tetrahydrofolic acid · Ademetionine · Pyruvic acid · Arginine · Adenosine phosphate +26 moreEnzymes: Betaine--homocysteine S-methyltransferase 1Ibrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalIt is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. … Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-oneTralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigationalWhile AD is a heterogenous condition with a variety of apparent genetic and environmental causes,[A242422] it is primarily driven by the pro-inflammatory cytokine interleukin-13 (IL-13). … [A242427] Tralokinumab is a fully human IgG4 monoclonal antibody targeted against IL-13.